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Abstract
Background: Common single nucleotide polymorphisms (SNPs) in proprotein convertase subtilisin/kexin type 1 with
modest effects on PC1/3 in vitro have been associated with obesity in five genome-wide association studies and with
diabetes in one genome-wide association study. We here present a novel SNP and compare its biosynthesis, secretion and
catalytic activity to wild-type enzyme and to SNPs that have been linked to obesity.
Methodology/Principal Findings: A novel PC1/3 variant introducing an Arg to Gln amino acid substitution at residue 80
(within the secondary cleavage site of the prodomain) (rs1799904) was studied. This novel variant was selected for analysis
from the 1000 Genomes sequencing project based on its predicted deleterious effect on enzyme function and its
comparatively more frequent allele frequency. The actual existence of the R80Q (rs1799904) variant was verified by Sanger
sequencing. The effects of this novel variant on the biosynthesis, secretion, and catalytic activity were determined; the
previously-described obesity risk SNPs N221D (rs6232), Q665E/S690T (rs6234/rs6235), and the Q665E and S690T SNPs
(analyzed separately) were included for comparative purposes. The novel R80Q (rs1799904) variant described in this study
resulted in significantly detrimental effects on both the maturation and in vitro catalytic activity of PC1/3.
Conclusion/Significance: Our findings that this novel R80Q (rs1799904) variant both exhibits adverse effects on PC1/3
activity and is prevalent in the population suggests that further biochemical and genetic analysis to assess its contribution
to the risk of metabolic disease within the general population is warranted.
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Introduction
Prohormone convertase 1/3 is a calcium-dependent serine
endoprotease essential for the conversion of a variety of
prohormones and neuropeptide precursors to their bioactive
forms. Human prohormone convertase 1/3 (PC1/3) is encoded by
the gene PCSK1, which is located on chromosome 5 and is
comprised of 14 exons [1]. PC1/3 is expressed in a subset of
endocrine and neuroendocrine tissues, cells equipped with a
regulated secretory pathway. During transit through the secretory
pathway, PC1/3 is first synthesized in the endoplasmic reticulum
(ER) as an inactive 94 kDa zymogen composed of an N-terminal
signal peptide, a prodomain which serves as an intramolecular
chaperone and inhibitor; a catalytic domain which accomplishes
substrate hydrolysis; a P (homo B) domain which contributes to
enzymatic properties; and a carboxyl-terminal (CT) domain
which, when removed by partial or complete in trans proteolytic
processing, results in a much more active, but also less stable,
enzymatic form (reviewed in [2] (Figure 1). PC1/3 is abundantly
expressed in the arcuate and paraventricular nuclei of the
hypothalamus [3,4], tissues that are known to mediate satiety
and hunger signals [5]. Substrates of PC1/3, such as proinsulin,
proglucagon, proghrelin, agouti-related protein, pro-neuropeptide
Y, provasopressin and proopiomelanocortin are responsible for the
regulation of absorption, metabolism and acquisition (appetite) of
nutrients [6,7,8,9,10,11,12,13,14].
Deficiencies in PC1/3 frequently lead to imbalances in
prohormone processing that result in an array of metabolic
phenotypes, previously investigated both in mouse models and in
humans. Three human subjects have been described with an
autosomal recessive disorder (MIM:600955) associated with severe
mutations of PC1/3 resulting in early-onset obesity, hyperphagia,
hypoadrenalism, reactive hypoglycemia, malabsorptive diarrhea,
and hypogonadism [15,16,17]. Interestingly, the PC1/3 null
mouse model, unlike the PC1/3-deficient human, is not obese.
Although of normal weight at birth, PC1/3 null mice have a high
post-natal mortality rate, and those that do survive have a
significant reduction in body mass as compared to wild-type
animals by the age of 6 weeks. The stunted growth of PC1/3 null
mice is believed to be due at least in part to reduced processing of
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growth hormone releasing hormone (GHRH) and thus reduced
circulating levels of growth hormone (GH) [8]. In addition to a
reduction in GHRH, the levels of several key neuroendocrine
peptides such as ACTH, insulin and glucagon-like peptides-1 and -
2 are reduced in these animals due to lack of precursor processing
by PC1/3 [8].
While the PC1/3 null mouse is not obese, a mouse model of
obesity has been generated via introduction of a missense mutation
in PCSK1 at amino acid position 222, near the calcium-binding
pocket in the catalytic domain. This hypomorph mutation resulted
in obesity, hyperphagia and increased metabolic efficiency due to
decreased autocatalytic maturation of the enzyme to smaller
molecular weight forms [18]. Three common SNPs in PCSK1 have
been identified and associated with obesity. All three SNPs
(included in this study for comparison) exhibit moderate effects on
catalytic activity in vitro and on natural substrate processing in rat
pituitary tumor cells [19,20]. Two of the three non-deleterious
SNPs (S690T [rs6235] and Q665E [rs6234]) have been associated
with diabetes-related traits [20,21,22].
In the work presented below, the novel variant
NP_000430.3:p.Arg80Gln (R80Q; rs1799904), identified and
functionally evaluated for the first time here, was compared with
previously described SNPs associated with obesity and/or diabetes
(N221D [rs6232], Q665E/S690T [rs6234/rs6235], Q665E
[rs6234], and S690T [rs6235]) for potentially deleterious effects
on the biosynthesis, secretion and catalytic activity of PC1/3. Our
data suggest that this novel R80Q variant (rs1799904) deserves
further analysis to assess its genetic association with metabolic
diseases such as obesity and diabetes.
Materials and Methods
Databases used and protein structure/function analysis
methods
Alleles that varied from the human reference genome build
GRCh37 [23] were obtained from the dbSNP [24], 1000
Genomes [25], NHLBI [26], and NIEHS [27] datasets and were
merged into a custom SQL database. dbSNP data were compiled
from various sources, with allele frequencies available only for a
subset of variants. The 1000 Genomes dataset was based on both
low coverage whole genome and higher coverage exome
sequencing of 1092 individuals. The NHLBI and NIEHS data
were obtained from exome sequencing of 6500 and 95 individuals
respectively. Population allele frequencies were calculated using
the combined datasets wherever allele counts were present.
Variations in PCSK1 (chr5:95726119-95769847) were identified
and analyzed with the Ensembl Variant Effect Predictor version
2.6 [28] and Ensembl database homo_sapiens_variation_68_37
[29] to determine the effect of the variant on the transcript. Non-
synonymous codon substitutions were analyzed using the SIFT
[23,30,31,32,33], PolyPhen [34,35,36], and Condel [37] models to
estimate the variant’s probable impact on protein structure and
function.
Sanger sequencing of genomic DNA
Genomic DNA from individuals homozygous for two SNPs of
interest was isolated from EBV-infected B cells by the Coriell
Institute and sent to us for sequencing. The HG00596 DNA
sample containing rs1799904 (p.R80Q; (g.5:95764963C.T;
c.239G.A) was obtained from a southern Han Chinese female,
while the N586Tfsx4-containing (g.5:95730696TC.T;
c.1755delG) DNA sample, HG00350, was obtained from a
Finnish female. The primers used for sequencing bidirectionally
were:
Exon 2 (510 bp):
(F) CTCAACCAATTCAACCCAATC;
(R) CCCGTGACACAAGTTTACCTATG; and
Exon 13 (545 bp):
(F) CAGCTTTCCAAGAACACATCC;
(R) CCATGTTTGACTTATTTCCTGC
Expression vector construction/mutagenesis
Flag-tagged human PC1/3, a kind gift of J. W. Creemers [20]
was modified by site-directed mutagenesis using the Stratagene
Figure 1. Domain structure and SNP locations within preproPC1/3. The upward arrows indicate the cleavage sites required for PC1/3
maturation. The downward arrows indicate locations of previously described (black) and novel (purple) SNP. The dashed line between the pro and
catalytic domains represents a primary cleavage site (occurring in the ER) that is required for activation. The dashed line in the middle of the
prodomain indicates the secondary cleavage site (likely cleaved in the trans-Golgi network). The P or Homo B domain following the catalytic domain
is important for the stabilization of the catalytic domain, as well as determining various enzymatic properties. The C-terminal domain plays a role in
efficient routing of PC1/3 to the secretory granules, and contributes to substrate specificity as well as to specific activity and stability.
doi:10.1371/journal.pone.0055065.g001
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Table 1. Potentially consequential variant alleles in PCSK1.
Pos ID REF ALT Rank cDNA Protein Effect MAF Samples Het Hom
5:95768682 rs201377789 A G 12 65T.C Leu22Pro 0.00033 7690 5 0
5:95764976 G A 12 226C.T Pro76Ser 0.00008 6501 1 0
5:95764968 rs148354360 C A 12 234G.T Arg78Ser SpC 0.00015 6501 2 0
5:95764963 rs1799904 C T 12 239G.A Arg80Gln p 0.00870 1092 17 1
5:95761576 rs200893367 T G 12 344A.C Asp115Ala S 0.00046 1092 1 0
5:95761546 A T 12 374T.A Met125Lys 0.00008 6503 1 0
5:95761545 rs146545244 C T 12 375G.A Met125Ile 0.00038 6503 5 0
5:95759156 G A 12 404C.T Thr135Ile PC 0.00008 6503 1 0
5:95759151 T G 12 409A.C Met137Leu 0.00008 6503 1 0
5:95759098 rs145659863 T G 12 462A.C Lys154Asn S 0.00008 6503 1 0
5:95759093 A G 12 467T.C Ile156Thr SpC 0.00008 6503 1 0
5:95759090 rs200462856 G A 12 470C.T Thr157Met SPC 0.00015 6503 2 0
5:95759036 rs140520429 G A 12 524C.T Thr175Met SPC 0.00026 7595 4 0
5:95759019 rs145592525 A G 12 541T.C Tyr181His SPC 0.00038 6503 5 0
5:95757611 G A 12 593C.T Pro198Leu SPC 0.00008 6503 1 0
5:95751796 rs202203086 G A 12 650C.T Ala217Val SPC 0.00013 7595 2 0
5:95751785 rs6232 T C 12 661A.G Asn221Asp 0.03289 8254 523 10
5:95751745 rs145127903 T A 12 701A.T Lys234Ile SPC 0.00008 6503 1 0
5:95751742 rs183045011 A G 12 704T.C Val235Ala SPC 0.00046 1092 1 0
5:95748134 T C 12 770A.G Asn257Ser S 0.00008 6503 1 0
5:95748123 C T 12 781G.A Val261Met SPC 0.00008 6503 1 0
5:95748122 rs139602265 A G 12 782T.C Val261Ala SPC 0.00008 6503 1 0
5:95748068 rs142673134 C G 12 836G.C Gly279Ala SPC 0.00008 6503 1 0
5:95748035 rs193214131 T C 12 869A.G Tyr290Cys PC 0.00026 7595 4 0
5:95746664 G C 12 909C.G Phe303Leu SPC 0.00008 6503 1 0
5:95746663 rs148617898 C T 12 910G.A Val304Ile pC 0.00038 6503 5 0
5:95746638 rs138879299 C T 12 935G.A Arg312His S 0.00008 6503 1 0
5:95746543 rs189927028 C T 12 1030G.A Ala344Thr P 0.00046 1092 1 0
5:95744026 G A 12 1097C.T Thr366Met S 0.00008 6503 1 0
5:95735742 rs140481124 G C 12 1345C.G Leu449Val SPC 0.00008 6503 1 0
5:95735724 G T 12 1363C.A Pro455Thr SpC 0.00008 6503 1 0
5:95735703 rs151257336 G T 12 1384C.A Pro462Thr SpC 0.00008 6503 1 0
5:95735700 rs143174906 C T 12 1387G.A Glu463Lys 0.00059 7595 9 0
5:95734621 rs149124467 C T 12 1550G.A Arg517Gln pC 0.00015 6503 2 0
5:95734610 G A 12 1561C.T Leu521Phe SpC 0.00008 6503 1 0
5:95734581 A G 3 1588+2T.C - 0.00015 6503 2 0
5:95730719 rs145196120 A G 12 1733T.C Ile578Thr 0.00008 6503 1 0
5:95730638 C T 12 1814G.A Arg605His SPC 0.00008 6503 1 0
5:95730629 G A 12 1823C.T Thr608Met SpC 0.00015 6503 2 0
5:95730597 rs144324144 C G 12 1855G.C Gly619Arg P 0.00008 6503 1 0
5:95730576 G T 12 1876C.A Pro626Thr 0.00008 6503 1 0
5:95729049 rs139453594 T C 12 1918A.G Thr640Ala 0.00145 7595 22 0
5:95729048 rs193015519 G A 12 1919C.T Thr640Ile 0.00013 7595 2 0
5:95729039 rs142453906 G C 12 1928C.G Ser643Cys 0.00008 6502 1 0
5:95729007 rs200614230 G A 12 1960C.T Arg654Trp S 0.00046 1092 1 0
5:95728982 rs148807505 G T 12 1985C.A Ala662Asp S 0.00008 6503 1 0
5:95728974 rs6234 G C 12 1993C.G Gln665Glu 0.24962 7900 2988 478
5:95728898 rs6235 C G 12 2069G.C Ser690Thr 0.23747 7900 2852 450
5:95728877 rs138433207 T G 12 2090A.C Tyr697Ser 0.00008 6503 1 0
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QuikChange method [38] to introduce the mutations shown in
Figure 1. All mutations were verified by sequencing of the entire
PC1/3 cDNA insert.
Transient transfection of PC1/3 variants
To assess the biosynthesis and secretion profiles of PC1/3
variants in a cell line that does not express endogenous PC1/3,
Ad-293 (Stratagene) HEK cells, plated at a density of 26105 cells
per well in 24-well plates, were transfected with plasmids encoding
either wild-type or variant PC1/3s in triplicate wells. Cells were
transfected with 200 ng of plasmid DNA per well using
Lipofectamine (Invitrogen, Carlsbad, CA). To assess effects in a
regulated neuroendocrine cell line (also lacking expression of
endogenous PC1/3), Neuro-2A cells (ATCC, cat. No. CCL-131)
were transfected in triplicate with the same protocol using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). For both cell
lines, five hours post-transfection, 1 ml of growth medium was
added to each well and incubation continued for an additional
24 h. Cells were then washed with PBS and 0.3 ml of Opti-MEM
(Invitrogen, Carlsbad, CA) containing 100 ug/ml bovine aprotinin
(Desert Biologicals) was added to each well. Cells were incubated
for an additional 18–24 h before conditioned medium and cells
were harvested. Conditioned medium was analyzed first by
enzyme assay; both cells and medium samples (for HEK cells)
and medium samples (for Neuro- 2A cells) were then subjected to
SDS-PAGE followed by Western blotting using primary antiserum
against the amino terminus of mature mouse PC1/3 [39]. Mouse
monoclonal anti-ß-actin antiserum (Sigma-Aldrich, St. Louis, MO)
was used to assess cellular actin levels as a loading control. Western
blots were then probed with horseradish peroxidase-coupled
secondary antiserum. Visualization of immunoreactive protein
was accomplished using the SuperSignal West Femto Maximum
Sensitivity Substrate kit (Thermo Scientific, Rockford, IL).
Enzyme assay
Enzymatic activity of secreted recombinant PC1/3 proteins
present in conditioned medium obtained from transiently trans-
fected HEK293 cells was measured in triplicate 50 ul reactions in
a 96-well polypropylene plate containing 25 ul of conditioned
medium and final concentrations of 200 uM substrate (pyr-
ERTKR-amc [7-amino-4-methlcoumarin]), 100 mM sodium ac-
etate, pH 5.5, 2 mM CaCl2, 0.1% Brij 35, and a protease
inhibitor cocktail (final concentrations: 1 uM pepstatin, 0.28 mM
TPCK, 10 uM E-64, and 0.14 mM TLCK). Reaction mixtures
were incubated at 37uC and fluorescence measurements (380 nm
excitation, 460 emission) were taken under kinetic conditions every
20 seconds for 1 h in a SpectraMax M2 Microplate Reader.
Maximum rates were obtained from the linear portion of the
kinetic measurement curves. Specific activities of PC1/3 proteins
in the conditioned medium were determined by dividing
maximum rates by band intensities of total secreted immunore-
active protein, each determined in triplicate, and quantified with
an Alphaimager 3300 (Alpha Innotech Corporation, San Leandro,
CA) imaging system.
Results
Analysis of public databases; structure-function analysis
A total of 1020 allelic variants (data not shown) within the
PCSK1 gene were found in the public databases, of which 54 were
potentially consequential splice site or missense variants (Table 1).
Thirty-seven non-synonymous substitutions were predicted to be
possibly or probably deleterious by at least one model (SIFT,
PolyPhen, or Condel, where Condel represents a consensus
modeling program). Two of the three previously described variants
are common, with MAFs of 23.7% for S690T (rs6235) and 25.0%
for Q665E (rs6234), whereas the N221D SNP (rs6232) is less
common (MAF=3.3%). None of these three variants were
predicted to be deleterious using SIFT, PolyPhen, or Condel. In
contrast, the novel variants that were predicted as ‘‘possibly’’ or
‘‘probably’’ deleterious were unique to one sample or were
observed with very low frequency (minor allele frequencies (MAFs)
of 0.008%–0.87%. In addition we considered a frameshift variant
Table 1. Cont.
Pos ID REF ALT Rank cDNA Protein Effect MAF Samples Het Hom
5:95728863 rs140899352 C T 12 2104G.A Glu702Lys 0.00039 7595 6 0
5:95728862 rs188666266 T G 12 2105A.C Glu702Ala S 0.00046 1092 1 0
5:95728749 G A 12 2218C.T Arg740Trp SPC 0.00008 6503 1 0
5:95728748 rs140941383 C T 12 2219G.A Arg740Gln SPC 0.00008 6503 1 0
5:95728710 rs147016634 T G 12 2257A.C Asn753His SC 0.00046 7595 7 0
The R80Q (rs1799904) variant that differed from the human reference genome and was predicted to have a potentially consequential effect on the transcript was
selected from the dbSNP 137, 1000 Genomes, NHLBI, and NIEHS public datasets. Pos: genomic position in GRCh37; ID: dbSNP 137 rs ID; REF: reference allele; ALT:
alternate allele (variant); Rank: 3 splice_donor_variant, 12 missense_variant; cDNA: position and consequence of variant in cDNA of canonical NM_000439.4 transcript;
Protein: position and consequence of variant in NP_000430.3 protein; Effect: computational prediction of effect on protein structure or function (‘‘S’’ predicted
deleterious by SIFT, ‘‘P’’ or ‘‘p’’ predicted probably or possibly damaging by PolyPhen, ‘‘C’’, predicted deleterious by Condel from a consensus of SIFT and PolyPhen, ‘‘-’’
no prediction); MAF: minor allele frequency across all populations; Samples: total number of individuals genotyped; Het: number of individuals heterozygous for the
variant allele; Hom: number of individuals homozygous for the variant allele. Known, common variants are listed in italics, and the rare novel variant is shown in bold.
doi:10.1371/journal.pone.0055065.t001
Figure 2. Direct Sanger sequencing of genomic DNA from a
subject bearing the Arg80Gln variant.
doi:10.1371/journal.pone.0055065.g002
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N586TfX4 (g.5:95730696), which exhibited an unusually large
MAF of 6.1% in a previous release of the 1000 Genomes data. We
selected the most common novel variant R80Q (rs1799904;
MAF=0.87%), and N586TfsX4 for genomic sequencing and
potential functional studies, comparing them with already
described common variants of PC1/3.
SNP validation by sequencing
Genomic DNA from two individuals homozygous for the most
common variants was obtained from the Coriell Institute and
subjected to Sanger sequencing. The DNA sample containing
rs1799904 (R80Q (g.5:95764963C.T; c.239G.A) was found to
be homozygous for the R80Q mutation in exon 2 (Figure 2),
while the N586Tfsx4-containing SNP (g.5:95730696TC.T;
c.1755delG) was determined to be a false positive (i.e. no frameshift
mutation was found in in exon 13) (data not shown).
Secretion and biosynthesis of PC1/3 variants
In order to assess whether the novel variant R80Q (rs1799904)
affected the biosynthesis or secretion of PC1/3, expression vectors
encoding wild-type and variant PCSK1s were transiently transfect-
ed into HEK and/or Neuro-2a cells (both lines lack expression of
endogenous PC1/3). PC1/3 proteins containing the previously
described S690T/Q665E (rs6234/rs6235) pair, as well as the
individual S690T and Q665E SNPs, did not exhibit significantly
altered expression and secretion patterns as compared to wild-type
PC1/3. The N221D (rs6232) substitution resulted in reduced
secretion and cleaved forms of PC1/3 in the medium (Figure 3).
The secretion profile of the R80Q (rs1799904) substitution differed
Figure 3. Western blotting of wild-type and variant PC1/3 proteins expressed in HEK cells. HEK cells were transiently transfected with
empty pcDNA3 (E); pcDNA3 encoding either wild-type PC1/3; or PC1/3 proteins bearing the mutations under study. Western blots of cell lysates and
media from transfected HEK cells were probed with amino-terminally directed PC1/3 primary antiserum for detection of recombinant proteins. The
data shown represent 1 of 3 independent experiments performed in triplicate. Total secreted immunoreactive band intensity values, obtained
through densitometry analysis and used to calculate specific activity for each variant, are represented above the Western blot and shown as the mean
6 S.D.
doi:10.1371/journal.pone.0055065.g003
Figure 4. Specific activities of wild-type and variant PC1/3 proteins, expressed in HEK cells. Enzymatic activities of secreted recombinant
PC1/3 proteins in conditioned medium of transfected HEK cells were compared by measuring maximum cleavage rates using the fluorogenic
substrate pyr-ERTKR-amc during a 1 h kinetic assay. Three replicates per transfection condition were assayed in triplicate, and maximum rates were
divided by band intensity of immunoreactive protein in the spent medium of the same wells from which activity data were derived. Specific activity
values are shown as the mean 6 S.D (n = 3). Data represent one of 3 independent experiments performed in triplicate.
doi:10.1371/journal.pone.0055065.g004
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from wild-type PC1/3, in that the 74 and 66 kDa lower molecular
weight forms of PC1/3 were absent from the medium (in HEK cell
experiments) or reduced (in Neuro-2a cell experiments), although
the total level of secreted PC1/3 was not reduced.
Catalytic activity of PC1/3 variants
To determine the impact of these variations on PC1/3 catalytic
activity, conditioned medium of HEK cells transfected with either
empty vector, variant PC1/3s, or wild-type PC1/3 was subjected
to a fluorogenic assay. Maximum rates of fluorogenic substrate
cleavage were normalized using the band intensities of secreted
PC1/3s in order to determine the specific activity of each variant
relative to wild-type PC1/3. The S690T/Q665E (rs6234/rs6235)
and S690T (rs6234) amino acid substitutions did not significantly
alter specific activity (95% confidence level; p.0.13). The Q665E
substitution alone resulted in a small but significant 27% decrease
in specific activity as compared to wild-type (p= 0.05). The
N221D (rs6232) substitution decreased specific activity by 36%
(p= 0.02), and the R80Q variation resulted in a 38% decrease
(p = 0.02) (Figure 4). When expressed in Neuro-2a cells, the
R80Q (rs1799904) variant resulted in a 42–48% decrease
(p,0.0001) in activity as compared to wild-type PC1/3 (Figure 5).
Discussion
In studies of European populations, PCSK1 represents the third
most important gene contributing to extreme obesity [40].
Functional studies of certain SNPs associated with obesity that
impose modest or no significant effects on PC1/3 function in vitro
have supported the idea that even slight variations in PC1/3
activity can predispose an individual to higher risk of obesity [20].
Individuals who are compound heterozygotes or are homozygous
for rare severe deleterious mutations in PCSK1 suffer from multi-
dimensional disease states, including small intestinal dysfunction,
hyperphagia and obesity [15,16,17]. Even heterozygous mutations
which result in functional enzymatic changes have been linked to
obesity, despite the presence of a normal allele [40]. The
mechanism by which modest deficiencies in PC1/3 activity can
lead to such profound phenotypes when present on a single allele
remains unknown. A closer look into the complex biochemistry of
commonly found variations of this enzyme may provide answers to
these questions. In this work, we have analyzed public databases
for other less common and rare deleterious variants and identified
the variant R80Q (rs1799904), and have compared the effects of
this variant to those of known polymorphisms.
Consistent with previous studies [19,20], we found that the
amino acid substitutions S690T/Q665E (rs6234/rs6235) did not
significantly alter the specific activity or biosynthesis and secretion
of PC1/3 in HEK cells. The Q665E substitution alone did result
in a slight decrease in specific activity as compared to wild-type
enzyme, and may represent the more detrimental of the two
mutations (S690T/Q665E), which were previously identified as a
paired SNP associated with a higher risk of developing obesity and
diabetes [19,20,21]. In our hands, the N221D (rs6232) substitution
decreased specific activity by a somewhat greater extent than
previously reported, possibly due to differences in enzyme assay
methods [20].
However, of all of the variants we analyzed in HEK cells, the
novel R80Q (rs1799904) variant exhibited the most detrimental
effects on PC1/3 maturation and specific activity. This variant
yielded an 87 kDa product in the conditioned medium that did
not undergo further carboxy-terminal processing to the more
active 74 and 66 kDa forms, resulting in an enzyme with
significantly lower specific activity, similar to the more common
obesity risk N221D (rs6232) variant. This novel R80Q variant
exhibited an even more pronounced decrease in specific activity
when expressed in a cell line containing a regulated secretory
pathway (Neuro-2a), where wild-type PC1/3 is likely able to
achieve greater specific activity through more complete matura-
tion to its lower molecular weight forms within regulated secretory
vesicles. The lower molecular weight forms of PC1/3 exhibit a
different substrate specificity than full-length 87 kDa PC1/3 [41];
this could be an important mechanism for SNPs to exert functional
effects. Another possible functional consequence of altering the
profile of active species is a change in enzyme stability, since
carboxy-terminally truncated species are known to be more labile
than the 87 kDa form (reviewed in [2]). Since the C-terminal
region of PC1/3 has been implicated in targeting of this enzyme to
secretory granules [42,43], altered C-terminal processing may also
result in changes in enzyme distribution. Further studies using
immunocytochemistry in transfected Neuro- 2A cells will shed
additional light on this question.
The proPC1/3 maturation process begins with the autocatalytic
intramolecular cleavage of the pro-domain in the ER at the
primary cleavage site, RSKR107–110 [44,45]. This cleavage yields
an 87 kDa form of PC1/3 that, by analogy with the related
enzyme furin [46] likely remains associated with its own
Figure 5. Western blotting of wild-type and novel R80Q
(rs1799904) variant PC1/3s, expressed in Neuro-2A cells. Panel
A: Neuro-2a cells were transiently transfected with equal amounts of
empty pcDNA3 (E), or pcDNA3 encoding wild-type PC1/3 or the novel
variant R80Q (rs1799904) PC1/3. Western blots of media were probed
using amino-terminally directed PC1/3 primary antiserum. The data
shown represent one of 3 independent experiments performed in
triplicate. Panel B: Specific activities of wild-type PC1/3 and the
R80Q PC1/3 variant. Enzymatic activities of secreted recombinant
PC1/3 proteins in conditioned medium were compared by measuring
maximum cleavage rates using the fluorogenic substrate pyr-ERTKR-
amc during a 1 h kinetic assay. Three replicates per transfection
condition were assayed in triplicate, and maximum rates were divided
by band intensity of immunoreactive protein in the spent medium of
the same wells from which the activity data were derived. Specific
activity values are shown as the mean 6 S.D. Data represent one of 3
independent experiments, each performed in triplicate.
doi:10.1371/journal.pone.0055065.g005
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prodomain through non-covalent interactions until its arrival at
the trans-Golgi network. Although this has not yet been strictly
demonstrated for PC1/3, the PC1/3 prodomain most likely assists
in the folding of the catalytic domain and in enzyme inhibition
during secretory pathway transport [47,48,49,50,51,52]. If prodo-
main processing of PC1/3 occurs similarly to that of furin, trans-
Golgi network protonation of a histidine in the vicinity of the
secondary cleavage site (RRSRR77–81) then results in secondary
site cleavage at R81, followed by dissociation of prodomain
fragments from PC1/3 [53,54]. The inhibitory role of the
prodomain is of particular interest to this study when we consider
the location of the R80Q (rs1799904) substitution within the
secondary cleavage site of the prodomain (Figure 1). Independent
studies have shown that alteration of mouse proPC1/3 prodomain
residues either within or surrounding cleavage motifs can affect
propeptide processing; the in vitro proteolytic conversion of an
R80A mutant propeptide (the same residue as the R80Q variant
studied here) by wild-type enzyme was impaired compared to
wild-type propeptide [44]. Given this finding, our lack of
identification of propeptide-bearing R80Q PC1/3 is puzzling.
We have previously found that a portion of newly synthesized
proPC1/3 is subjected to endoplasmic reticulum- associated
degradation [52]; this might represent the fate of this molecular
species. Collectively, these data support the idea that residues
within the secondary cleavage site, including the novel variant
studied here, contribute to the proper processing of proPC1/3.
The novel R80Q (rs1799904) variant (MAF=0.87%) is about
one-third as common as the N221D (rs6232) SNP (MAF=3.3%).
Although less common, the R80Q variant should be subjected to
further analysis to evaluate its influence on insulin sensitivity,
proinsulin conversion and the risk of developing obesity, similarly
to the effect of the N221D (rs6232) SNP [20,22]. We note that 119
individuals in the public datasets have other, less common and
rare variants of PCSK1, most of which are predicted to have some
detrimental effect on protein function. This mutational burden on
the population is not trivial and may also play a role in
susceptibility to obesity or other disorders. The importance of
rare variants in common disorders is not clear at present, but
advances in massively parallel sequencing and computational
analysis may soon shed additional light on this question.
In conclusion, we show that the novel PCSK1 variant R80Q
(rs1799904) exhibits deleterious effects on PC1/3 maturation. This
PC1/3 variant exhibits decreased catalytic activity as compared to
wild-type PC1/3 and to previously described obesity risk SNPs;
therefore, it may contribute to a higher risk of metabolic disease in
the general population. Our results suggest that further study of
less common and rare variations in PCSK1 from both biochemical
and genetic standpoints will be useful in elucidating the
mechanisms by which variant PC1/3s contribute to metabolic
diseases such as obesity and diabetes.
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